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The blood coagulation factor thrombin that leaks from ruptured vessels initiates brain tissue 
damage after intracerebral hemorrhage.  We have recently shown that mitogen-activated 
protein kinases (MAPKs) activated by thrombin exacerbate hemorrhagic brain injury via 
supporting survival of neuropathic microglia.  Here, we investigated whether induction of 
heme oxygenase (HO)-1 is involved in these events.  Zinc protoporphyrin IX (ZnPP IX), a 
HO-1 inhibitor, attenuated thrombin-induced injury of cortical cells in a 
concentration-dependent manner (0.3-3 M) and tended to inhibit shrinkage of the striatal 
tissue at 0.3 M.  HO-1 expression was induced by thrombin in microglia and astrocytes in 
both the cortex and the striatum.  The increase of HO-1 protein was suppressed by a p38 
MAPK inhibitor SB203580, and early activation of p38 MAPK after thrombin treatment was 
observed in neurons and microglia in the striatum.  Notably, concomitant application of a 
low concentration (0.3 M) of ZnPP IX with thrombin induced apoptotic cell death in striatal 
microglia and significantly decreased the number of activated microglia in the striatal region.  
On the other hand, a carbon monoxide releaser reversed the protective effect of ZnPP IX on 
thrombin-induced injury of cortical cells.  Overall, these results suggest that p38 
MAPK-dependent induction of HO-1 supports survival of striatal microglia during thrombin 
insults.  Thrombin-induced cortical injury may be also regulated by the expression of HO-1 
and the resultant production of heme degradation products such as carbon monoxide. 
 
Section : 8. Disease-Related Neuroscience 
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ABBREVIATIONS 
ERK: extracellular signal-regulated kinase 
HO: heme oxygenase 
JNK: c-Jun N-terminal kinase 
MAPK: mitogen-activated protein kinase 
Nrf2: nuclear respiratory factor 
PAR: protease-activated receptor 
RuCO: tricarbonyldichlororuthenium (II) dimmer 
ZnPP IX: zinc (II) protoporphyrin IX 
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INTRODUCTION 
 Blood intrinsic factors leak into brain parenchyma during hemorrhagic stroke (Park et al., 
2005; Belayev et al., 2005).  Among these factors, thrombin plays an important role in the 
pathogenesis of intracerebral hemorrhage, while it is well known as a blood coagulation factor 
(Kitaoka et al., 2002; Xi et al., 2006).  Serine protease activity of thrombin cleaves 
proteinase-activated receptors in neurons and glia, resulting in neuronal injury and glial 
overactivation (Flynn and Buret, 2004; Striggow et al., 2001; Noorbakhsh et al., 2003).  
Stimulation of proteinase-activated receptors drives a variety of intracellular signaling, 
including mitogen-activated protein kinase (MAPK) pathways (Marinissen et al., 2003; Suo et 
al., 2003; Wang et al., 2002).  Our previous studies have shown that inhibition of 
extracellular signal-regulated kinase (ERK), p38 MAPK and c-Jun N-terminal kinase (JNK) 
attenuates thrombin-induced injury of striatal tissue in both in vitro and in vivo models 
(Fujimoto et al., 2006, 2007).  Interestingly, these MAPK inhibitors induce apoptotic cell 
death in activated microglia, which may contribute to the neuroprotective effect of these drugs 
in collagenase-induced intracerebral hemorrhage model in vivo and in thrombin-treated 
corticostriatal slice cultures (Ohnishi et al., 2007; Ohnishi et al., 2010).  These effects of 
MAPK inhibitors suggest that MAPKs are required to maintain survival of activated 
microglia in hemorrhagic brain.  However, detailed mechanisms of MAPK-mediated 
maintenance of microglial survival remain to be explored. 
Heme oxygenase (HO)-1 is an inducible isoform of heme-degrading enzyme whose 
expression is regulated by MAP kinases as well as by nuclear respiratory factor 2 (Nrf2; Ryter 
et al., 2006).  In hemorrhagic brain of mice, HO-1 expression is mainly observed in 
microglia/macrophages and vascular endothelial cells around the hematoma region.  
Deletion of HO-1 gene results in diminution of hemorrhage-induced brain tissue injury (Wang 
and Doré, 2007).  Notably, HO-1 deletion is also associated with a decreased number of 
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activated microglia/macrophages after intracerebral hemorrhage (Wang and Doré, 2007), 
suggesting that HO-1 supports survival of activated microglia.  Another line of evidence 
suggesting the role of HO-1 in microglia is that microglial BV-2 cells expressing HO-1 are 
resistant to various cytotoxic factors such as staurosporine and nitric oxide (Lee and Suk, 
2007). 
Accordingly, the present study was aimed to reveal whether HO-1 is involved in 
MAPK-dependent survival of activated microglia and contributes to pathological events under 
hemorrhagic conditions.  For this purpose, we used thrombin-induced injury model of 




HO-1 inhibitor attenuates thrombin-induced cortical cell injury 
 As reported previously by us (Fujimoto et al., 2006; Ohnishi et al., 2009; Ohnishi et al., 
2010), application of 100 U/ml thrombin to corticostriatal slice cultures for 72 h led to 
substantial cell death in the cortical region as revealed by an increase in the intensity of 
propidium iodide fluorescence.  In addition, thrombin at 100 U/ml induced prominent 
shrinkage of the striatal region.  First we examined the effect of ZnPP IX, a HO-1 inhibitor, 
on thrombin-induced injury.  Thrombin-induced injury in the cortical region was attenuated 
by concomitant application of ZnPP IX (0.3–3 M) for 72 h in a concentration-dependent 
manner, and the effect reached statistical significance at 1 and 3 M (Figs. 1A–G).  As for 
the striatal region, ZnPP IX tended to suppress thrombin-induced shrinkage of the striatal 
tissue at 0.3 M, although the effect diminished as the concentration of ZnPP IX increased to 
1 and 3 M (Figs. 1A–F, H).  ZnPP IX at concentrations lower than 0.3 M had no 
significant effect (data not shown). 
 
HO-1 expression is induced in glial cells by thrombin 
 Next we examined profiles of HO-1 expression in corticostriatal slice cultures.  Western 
blot analysis of whole slice cultures revealed that expression of HO-1 was robustly increased 
after 12 h of thrombin treatment (Figs. 2A and B).  To identify cell types expressing HO-1, 
double immunofluorescence staining with a neuronal marker (MAP-2), a microglial marker 
(Iba1) and an astrocyte marker (GFAP) was performed in slices treated with thrombin for 24 h.  
HO-1 expression was observed in microglia and astrocytes but not in neurons in both cortical 
and striatal regions (Figs. 2C–K).  Double immunofluorescence staining with NeuN also 
confirmed that HO-1 was not expressed in neurons (data not shown). 
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p38 MAPK mediates HO-1 expression by thrombin 
 To investigate the involvement of MAP kinase pathways in thrombin-induced expression 
of HO-1, we examined the effects of MAPK inhibitors.  Inhibitors of MAPK/ERK kinase 
(PD98059), p38 MAPK (SB203580), or JNK (SP600125) were applied at 100 M 
concomitantly with 100 U/ml thrombin for 24 h.  As shown in Fig. 3, inhibition of p38 
MAPK by SB203580 potently and significantly suppressed thrombin-induced increase in 
HO-1 expression.  In contrast, PD98059 and SP600125 had no significant effect. 
 In a previous study, we demonstrated that thrombin-induced phosphorylation of p38 
MAPK peaked at 1 h in corticostriatal slice cultures (Ohnishi et al., 2010).  Accordingly, we 
examined slice cultures treated with thrombin for 1 h, by double immunofluorescence staining 
to reveal which cell types were responsible for the increase in p38 MAPK phosphorylation.  
In the striatal region, the phosphorylated form of p38 MAPK colocalized with 
immunoreactivity against OX42, a microglial marker, as well as that against NeuN, a neuronal 
marker.  Astrocytes, identified by GFAP immunoreactivity, did not exhibit immunopositive 
signals against phosphorylated p38 MAPK (Fig. 4).  p38 MAPK phosphorylation was not 
evident in the cortical region. 
 
HO-1 inhibitor induces apoptotic cell death in striatal microglia 
 Both activation of p38 MAPK and expression of HO-1 were observed in striatal microglia 
after thrombin treatment (Figs. 2F–H and 4D–F).  In addition, SB203580 suppressed 
thrombin-induced increase of HO-1 expression (Fig. 3).  Moreover, we have shown 
previously that MAPKs including p38 MAPK maintain survival of microglia activated by 
thrombin (Ohnishi et al., 2007; Ohnishi et al., 2010).  These findings are consistent with the 
idea that p38 MAPK-mediated expression of HO-1 is involved in microglial survival.  
Therefore, we examined the effect of ZnPP IX on the viability of microglia in 
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thrombin-treated slice cultures.   As reported (Ohnishi et al., 2010), 72-h application of 100 
U/ml thrombin robustly increased the number of OX42-positive activated microglia in the 
striatal region.  ZnPP IX at 0.3 M concomitantly applied with thrombin attenuated the 
increase of microglia (Figs. 5A–D), although higher concentrations (1 and 3 M) of this 
compound were less effective. 
We further examined the effect of 0.3 M ZnPP IX with regard to the ability to induce cell 
death in microglia by examining nuclear condensation and fragmentation.  In this context, 
we have previously demonstrated that thrombin in the presence, but not in the absence, of 
MAPK inhibitors induces apoptotic changes in nuclear morphology in microglia (Ohnishi et 
al., 2010).  Here, Hoechst 33342 staining combined with OX42 immunofluorescence 
histochemistry revealed that concomitant application of 0.3 M ZnPP IX with 100 U/ml 
thrombin for 48 h induced nuclear condensation and fragmentation in a significant population 
of microglia in the striatal region (Figs. 5E–I). 
 
Possible involvement of carbon monoxide in HO-1-mediated cortical cell injury 
 The above results suggest that HO-1 maintains survival of activated microglia to 
accelerate thrombin-induced striatal cell injury.  However, this scenario does not apply to the 
case with the cortex because thrombin induces cortical cell injury in a microglia-independent 
manner (Fujimoto et al., 2006).  To gain insights into the mechanisms of the effect of ZnPP 
IX on cortical cell injury (Fig. 1), we examined possible involvement of heme catabolites 
produced by HO-1 enzymatic activity in thrombin-induced cell death.  HO-1 catabolizes 
heme into carbon monoxide, biliverdin, and free iron.  Biliverdin is subsequently 
metabolized by biliverdin reductase to bilirubin (Maines, 1988), which, in general, shows 
cytoprotective activity (Doré et al., 1999; Yamamoto et al., 2010).  Indeed, application of 
bilirubin (1–100 M) to slice cultures did not induce cell death (data not shown).  Then, we 
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tested the effects of a carbon monoxide releaser RuCO, and an iron chelator deferoxamine.  
The Protective effect of 3 M ZnPP IX against thrombin-induced cortical cell injury was 
reversed by RuCO at concentrations of 10 and 30 M, a concentration range that showed no 
cytotoxicity by itself (Fig. 6A).  In addition, higher concentrations of RuCO alone increased 
propidium iodide fluorescence in the cortical region in a concentration-dependent manner, and 
significant cytotoxicity was observed at 300 M (data not shown).  On the other hand, 
deferoxamine (3–30 M) partially attenuated thrombin cytotoxicity.  The protective effect of 
deferoxamine reached statistical significance at 10 M but did not show concentration 
dependency (Fig. 6B).  We could not examine the effect of another iron chelator, 
phenanthroline, due to the cytotoxicity of its own. 
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DISCUSSION 
 The initial aim of the present study was to reveal whether HO-1 was involved in 
MAPK-dependent microglial survival that may exacerbate hemorrhage-associated brain injury.  
The results indicated that thrombin application to corticostriatal slice cultures induced HO-1 
in striatal microglia in a p38 MAPK-dependent manner, which participated in microglial 
survival in the striatum.  On the other hand, we also found that HO-1 may be involved in 
cortical cell injury via generation of heme degradation products such as carbon monoxide. 
 After application of thrombin, HO-1 expression was induced in microglia and astrocytes 
but not in neurons, both in the cortex and in the striatum.  These profiles are reminiscent of 
the expression pattern in the brain after intracerebral hemorrhage, where 
microglia/macrophages or endothelial cells around hemorrhage region, but not neurons, show 
intense HO-1 expression (Wang and Doré, 2007).  The major signaling pathway leading to 
HO-1 induction involves activation of Nrf2 by oxidative stress (Prestera et al., 1995; Alam et 
al., 1999), but other signaling pathways can be also involved (Ryter et al., 2006).  Of 
members of MAPK family, ERK and p38 MAPK are implicated in HO-1 expression in 
macrophages (Chen et al., 2002; Lee et al., 2003).  In the present study, SB203580 
substantially inhibited HO-1 induction, suggesting that p38 MAPK plays a major role in 
HO-1 expression in thrombin-treated slice cultures.  In this context, a recent study 
demonstrated that methamphetamine-induced HO-1 expression in primary cortical 
neuron/glia cocultures was dependent on p38 MAPK but not on ERK or JNK (Huang et al., 
2009).  p38 MAPK may contribute to HO-1 expression by promoting nuclear translocation 
of Nrf2 (Hwang and Jeong, 2008).  We also demonstrated that, in the striatal region, p38 
MAPK phosphorylation is induced by thrombin in microglia as well as in neurons.  These 
results are consistent with the idea that p38 MAPK mediates HO-1 induction by thrombin in 
striatal microglia. 
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 The number of OX42-positive activated microglia increased in response to thrombin.  
This is consistent with our previous study (Ohnishi et al., 2010) and also with a study by 
another group demonstrating that thrombin induces proliferation of microglia in primary 
culture (Suo et al., 2002).  In addition, our previous study has shown that inhibition of p38 
MAPK induces apoptotic cell death in striatal microglia and reduces the number of microglia 
in thrombin-treated slice cultures (Ohnishi et al., 2010).  In the present study, we showed that 
an optimal concentration of ZnPP IX also induced apoptotic cell death in striatal microglia 
and reduced the number of microglia in thrombin-treated slice cultures.  Therefore, these 
results indicate that HO-1 induction under control of p38 MAPK contributes to the 
maintenance of survival of activated microglia in the striatal region.  Maintained survival of 
activated microglia should be harmful to neurons, as activated microglia produce diffusible 
cytotoxic factors such as nitric oxide and cytokines.  Indeed, application of SB203580 or 
depletion of microglia almost completely inhibits thrombin-induced shrinkage of striatal 
tissue (Fujimoto et al., 2006).  SB203580 also significantly attenuates the decrease in the 
number of striatal neurons after intracerebral hemorrhage in vivo, which was associated with a 
decrease in the number of activated microglia (Ohnishi et al., 2007). 
 Given the fact that ZnPP IX reduced the number of striatal microglia in thrombin-treated 
slice cultures, one would expect that this drug also attenuates thrombin-induced striatal injury.  
However, we observed only a marginal effect of ZnPP IX on thrombin-induced shrinkage of 
the striatal region.  Moreover, the effect of ZnPP IX against thrombin-induced striatal 
shrinkage tended to disappear as the concentration of ZnPP IX increased.  We have no 
definitive explanations for these results, although the effect of ZnPP IX on striatal shrinkage 
seems to closely correlate with that on the number of microglia.  A fact to be considered is 
that ZnPP IX only partially decreased the number of activated microglia, which may not be 
sufficient to produce a significant protective effect on the viability of the striatal tissue.  
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Another possible cause is the involvement of HO-1 in cells other than microglia.  That is, 
astrocytes in addition to the microglia expressed HO-1 in response to thrombin treatment, and 
HO-1 in astrocytes may be important for maintaining viability of these cells (Teng et al., 
2004; Chen-Roetling et al., 2005).  Since ZnPP IX does not discriminate HO-1 in different 
cell types, inhibition of HO-1 in astrocytes might reduce astrocyte-dependent tissue integrity 
and cancel the beneficial effect resulting from inhibition of HO-1 in microglia. 
 In contrast to the case with the striatal region, ZnPP IX showed a protective effect on 
cortical cell injury in a concentration-dependent manner.  Totally distinct mechanisms are 
thought to mediate the protective effect of ZnPP IX in the cortical region than that in the 
striatal region because the mechanisms of thrombin-induced injury themselves differ between 
these two brain regions.  A notable difference is that thrombin-induced cortical injury 
proceeds in a microglia-independent manner (Fujimoto et al., 2006).  The fact that inhibition 
of p38 MAPK had no effect on cortical injury (Fujimoto et al., 2006) also highlights a 
different aspect of thrombin cytotoxicity in the cortex from that in the striatum.  Therefore, 
HO-1-mediated acceleration of cortical injury should be explained irrespective of microglia as 
well as of p38 MAPK.  Accordingly, we examined possible involvement of heme 
degradation products and found that supplementation of carbon monoxide by RuCO reversed 
the protective effect of ZnPP IX.  These results present a novel mechanism of cytotoxicity in 
that generation of carbon monoxide may participate in thrombin-induced cortical cell injury.  
Finally, we should note that an iron chelator deferoxamine also provided a partial but 
significant protective effect against cortical injury.  In this context, several reports have 
suggested involvement of iron in the pathogenesis of intracerebral hemorrhage (Hua et al., 
2007; Wan et al., 2009). 
 Overall, the present study showed that HO-1 was involved in thrombin-induced pathology 
in the striatum and in the cortex, although the roles of HO-1 in these two brain regions were 
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different.  In the striatum, HO-1 is induced in a p38 MAPK-dependent manner in activated 
microglia to inhibit microglial cell death.  In the cortex, HO-1 accelerates cortical cell injury 
possibly via production of heme degradation products such as carbon monoxide.  
Manipulation of HO-1 expression, either in a brain region-specific manner or in a cell 
type-specific manner, may provide further insights into the roles of HO-1 in the pathogenesis 




Drugs and Chemicals 
Drugs and chemicals were obtained from Nacalai Tesque (Kyoto, Japan), unless otherwise 
indicated.  Thrombin from bovine plasma (catalog no. T4648), deferoxamine and 
tricarbonyldichlororuthenium (II) dimmer (RuCO) were obtained from Sigma-Aldrich (St. 
Louis, MO, USA).  PD98059, SB203580 and zinc (II) protoporphyrin IX (ZnPP IX) were 
obtained from Calbiochem (San Diego, CA, USA).  SP600125 was obtained from Tocris 
Cookson (Bristol, UK).   
 
Preparation of Slice Cultures 
Experimental procedures in the present study were approved by our institutional animal 
experimentation committee, and animals were treated in accordance with the Guidelines of 
the Unites States National Institutes of Health regarding the care and use of animals for 
experimental procedures.  Organotypic slice cultures were prepared according to the 
methods described previously (Fujimoto et al., 2006; Ohnishi et al., 2009; Ohnishi et al., 
2010).  Briefly, Wistar rats at postnatal days 3–4 (Nihon SLC, Shizuoka, Japan) were 
anesthetized by hypothermia, and brains were removed from the skull and separated into two 
hemispheres.  Each hemisphere was cut into coronal slices of 300 m thickness under sterile 
conditions.  Six corticostriatal tissue slices were transferred onto a 30-mm Millicell-CM 
insert membrane (Millipore, Bedford, MA, USA) in six-well plates.  Culture medium, 
consisting of 50% minimum essential medium/HEPES (GIBCO, Invitrogen Japan, Tokyo, 
Japan), 25% Hanks’ balanced salt solution (GIBCO), and 25% heat-inactivated horse serum 
(GIBCO) supplemented with 6.5 mg/ml D-glucose and 2 mM L-glutamine, 100 U/ml 
penicillin G potassium, and 100 g/ml streptomycin sulfate (GIBCO), was supplied at 0.75 
ml/well.  Culture medium was exchanged for fresh one on the next day of culture 
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preparation, and thereafter, every 2 days.  Slices were cultured in a humidified atmosphere of 
5% CO2 and 95% air at 34 C.   
 
Drug Treatment and Cell Death Assessment 
Cultured slices at 9–11 days in vitro were incubated for 24–48 h in serum-free medium, 
where minimum essential medium/HEPES substituted for horse serum.  Then slices were 
exposed to 100 U/ml thrombin and other drugs dissolved in serum-free medium for indicated 
periods.  To assess cell injury, propidium iodide (5 g/ml) was added to serum-free medium 
for thrombin treatment.  Propidium iodide fluorescence was observed with an 
epifluorescence microscope equipped with a rhodamine filter set and a 10  objective lens.  
Fluorescence images were captured through a monochrome chilled CCD camera (C5985; 
Hamamatsu Photonics, Hamamatsu, Japan).  The intensity of each pixel was expressed as an 
8-bit signal, and the average signal intensity in an area of 180 m  180 m within the 
parietal cortex was obtained as the fluorescence value of each slice, with the use of NIH 
Image 1.63 software.  Slice cultures treated with 100 M N-methyl-D-aspartate for 72 h were 
used to determine the degree of the standard injury.  Fluorescence values were normalized 
with the intensity in cultures that received standard injury as 100%.  Images of whole slice 
cultures were also obtained through a 1  objective lens.  To estimate the area of the striatal 
region, we examined an image of propidium iodide fluorescence with increased gain, which 
revealed the entire morphology of a given slice probed by background fluorescence.  With 
this image, we delineated the boundary of the striatal region and quantified the area with NIH 
Image 1.63 software. 
 
Immunohistochemistry and Nuclear Staining 
After drug treatment, slice cultures were fixed with 4% paraformaldehyde in 0.1 M 
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phosphate buffer containing 4% sucrose for 2 h.  After rinsing with phosphate-buffered 
saline, they were permeabilized and blocked by 0.5% Triton X-100 in phosphate-buffered 
saline containing 3% goat or horse serum, then incubated with rabbit anti-MAP-2 (1:600; 
Sigma-Aldrich), rabbit anti-Iba1 (1:500; Wako Pure Chemicals, Osaka, Japan), rabbit 
anti-glial fibrillary acidic protein (GFAP; 1:1000; Dako A/S, Glostrup, Denmark), mouse 
anti-NeuN (1:200; Millipore), mouse anti-OX42 (1:300; Dainippon-Sumitomo 
Pharmaceutical, Osaka, Japan), mouse anti-GFAP (1:1000; Sigma-Aldrich), mouse anti-HO-1 
(1:5000; Stressgen Bioreagents, Ann Arbor, MI, USA), and rabbit anti-phospho-p38 MAPK 
(T180/Y182) (1:50; Cell Signaling Technology) as primary antibodies overnight at 4 C.  
After rinsing with phosphate-buffered saline, slices were incubated with Alexa Fluor 
488-labeled goat anti-mouse IgG (1:200; Molecular Probes, Eugene, OR, USA), Alexa Fluor 
594-labeled goat anti-rabbit IgG (1:200; Molecular Probes), and biotinylated anti-mouse IgG 
(1:200; Vector Laboratories, Burlingame, CA, USA) as secondary antibodies for 1 h at room 
temperature.  After incubation with the biotinylated secondary antibody, slices were treated 
with avidin-biotinylated horseradish peroxidase complex (Vectastain Elite ABC kit, Vector 
Laboratories) and then peroxidase was visualized with diaminobenzine and H2O2.  
Bright-field images were captured through a monochrome chilled CCD camera and stored as 
image files.  Immunofluorescence signals were acquired through a laser-scanning confocal 
microscopic system (MRC1024, BioRad, Hercules, CA, USA). 
For observation of microglial nuclei, cultures processed for OX42 immunohistochemistry 
as mentioned above were incubated with 0.1 mg/ml Hoechst 33342 (Molecular Probes) for 15 
min.  Fluorescence signals were acquired through an epifluorescence microscope (BZ-8000, 
KEYENCE, Osaka, Japan). 
 
Western blot analysis 
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After treatment with thrombin for the indicated periods, slices were harvested and 
homogenized in ice-cold lysis buffer containing 20 mM Tris–HCl (pH 7.0), 25 mM 
-glycerophosphate (Sigma), 2 mM EGTA2Na, 1% Triton X-100, 1 mM vanadate, 1% 
aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride, and 2 mM dithiothreitol.  Samples 
were mixed with a sample buffer composed of 124 mM Tris–HCl (pH 6.8), 4% sodium 
dodecyl sulfate (SDS), 10% glycerol, 0.02% bromophenol blue, and 4% 2-mercaptoethanol.  
After boiling for 5 min, samples were subjected to 12% SDS–polyacrylamide gel 
electrophoresis for around 90 min, followed by transfer to polyvinylidene difluoride 
membrane (Millipore) for 35 min.  Membranes were blocked for at least 1 h by 5% nonfat 
milk at room temperature and subsequently incubated overnight with mouse anti-HO-1 
(1:50,000) and anti--actin (1:100,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA).  
The membranes were rinsed and incubated with ECL anti-rabbit IgG, horseradish peroxidase 
linked whole antibody (from donkey) (1:2000; GE Healthcare, UK).  After incubating with 
secondary antibodies, membranes were rinsed, and bound antibodies were detected with 




Data are expressed as means  SEM.  Statistical significance of difference was evaluated 
with one-way analysis of variance followed by Student–Newman–Keuls’ test, unless 
otherwise indicated.  When the data sets were not suitable for parametric tests, 
nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used.  
Probability values less than 5% were considered significant. 
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Figure legends 
Fig. 1.  Effect of ZnPP IX, a HO-1 inhibitor, on thrombin-induced injury.  (A–F)  
Representative images of propidium iodide fluorescence of whole slice cultures after 72 h of 
treatment with 100 U/ml thrombin in the absence and the presence of 0.3–3 M ZnPP IX.  
Broken lines indicate areas of the cerebral cortex (Cx) and the striatum (St).  Scale bar = 1 
mm.  (G) Summary of the effect of ZnPP IX on thrombin-induced cortical cell injury as 
assessed by the intensity of propidium iodide fluorescence.  (H) Summary of the effect of 
ZnPP IX on thrombin-induced shrinkage of the striatal tissue.  The number of slices 
examined for each condition ranged between 36 and 48.  *** P < 0.001 vs. control; 
##
 P < 
0.01, 
###
 P < 0.001 vs. thrombin alone. 
 
Fig. 2.  Thrombin-induced HO-1 expression.  (A) Representative blots of HO-1 expression 
in response to thrombin.  Homogenates were prepared from whole slice cultures treated with 
100 U/ml thrombin for indicated periods, and lysates were subjected to Western blot analysis 
with specific antibodies against HO-1 and -actin.  Slices without thrombin treatment (0 h) 
were used as control.  (B) Time course of HO-1 expression.  Ratio of HO-1 vs. -actin at 
each time point was normalized by the ratio at time 0.  n = 4.  (C–K): Confocal 
microscopic images of immunofluorescence of HO-1 with MAP-2 (C–E), Iba1 (F–H), or 
GFAP (I–K) and their merged images (E, H, K) in slice cultures treated with thrombin for 24 
h.  Arrows indicate colocalization.  Scale bar = 50 m. 
 
Fig. 3.  Effects of MAP kinase inhibitors on thrombin-induced HO-1 expression.  (A) 
Western blot analysis was performed on slice cultures that received 100 U/ml thrombin 
treatment with or without PD98059 (PD; 100 M), SB203580 (SB; 100 M), and SP600125 




 P < 0.05 vs. thrombin alone, based on nonparametrical Kruskal–Wallis test 
followed by Dunn’s multiple comparisons test (n = 4). 
 
Fig. 4.  Identification of cell types that exhibit p38 MAPK activation in response to thrombin 
treatment.  Shown are confocal microscopic images of immunofluorescence of 
phosphorylated p38 MAPK (P-p38; B, E, H) with NeuN (A), OX42 (D), or GFAP (G) and 
their merged images (C, F, I) in slice cultures treated with 100 U/ml thrombin for 1 h.  
Arrows indicate colocalization.  Scale bar = 50 m. 
 
Fig. 5.  Microglial apoptosis induced by HO-1 inhibitor.  (A-C) Representative images of 
OX42-immunostained slices after 72 h of treatment with 100 U/ml thrombin.  Where 
indicated, 0.3 M ZnPP IX was concomitantly applied for 72 h.  Scale bar = 100 m.  (D) 
Summary of the effect of ZnPP IX (0.3–3 M) on thrombin-induced increase in the number of 
OX42-positive cells in the striatal region.  The number of slices examined for each condition 
ranged between 12 and 18.  *** P < 0.001 vs. control; 
##
 P < 0.01 vs. thrombin alone.  
(E–H) Hoechst 33342 nuclear staining of striatal microglia after 48 h of treatment with 100 
U/ml thrombin in the absence and the presence of 0.3 M ZnPP IX.  Arrows indicate 
condensed nuclei of OX42-positive microglia.  Panel H is a magnified view of the area 
denoted by a square in panel G.  Scale bar = 50 m (E–G) and 5 m (H).  (I) Summary of 
the effect of ZnPP IX combined with thrombin on the appearance of apoptotic nuclei in 
striatal microglia.  The number of slices examined for each condition ranged between 9 and 
12.  
###
 P < 0.001 vs. thrombin alone. 
 
Fig. 6.  Contribution of heme catabolites to thrombin-induced injury of cortical cells.  (A) 
Effect of RuCO (10–100 M) on the protective effect of 3 M ZnPP IX against thrombin 
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(100 U/ml)-induced cortical cell injury.  Drugs were concomitantly applied for 72 h, and 
cortical cell injury was assessed by the intensity of PI fluorescence.  The number of slices 
examined for each condition ranged between 18 and 24.  *** P < 0.001 vs. control; 
###
 P < 
0.001 vs. thrombin alone; 
+
 P < 0.05, 
+++
 P < 0.001 vs. thrombin plus ZnPP IX.  (B) Effect of 
concomitant application of deferoxamine (3–30 M) on cortical cell injury induced by 72 h of 
treatment with 100 U/ml thrombin.  The number of slices examined for each condition 
ranged between 24 and 42.  *** P < 0.001 vs. control; 
#
 P < 0.05 vs. thrombin alone. 






